Influence of ADAMTS13 deficiency on venous thrombosis in mice

• References

• 1 Brill A, Fuchs TA, Chauhan AK. et al. von Wille-brand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood 2011; 117: 1400-1407.
• 2 von Bruhl ML, Stark K, Steinhart A. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209: 819-835.
• 3 Fuchs TA, Brill A, Wagner DD. Neutrophil extra-cellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol 2012; 32: 1777-1783.
• 4 Diaz JA, Hawley AE, Alvarado CM. et al. Thrombogenesis with continuous blood flow in the inferior vena cava. A novel mouse model. Thromb Haemost 2010; 104: 366-375.
• 5 Fuchs TA, Brill A, Duerschmied D. et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010; 107: 15880-15885.
• 6 Motto DG, Chauhan AK, Zhu G. et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005; 115: 2752-2761.
• 7 Banno F, Kokame K, Okuda T. et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 2006; 107: 3161-3166.
• 8 Banno F, Chauhan AK, Miyata T. The function of ADAMTS13 in thrombogenesis in vivo: insights from mutant mice. Int J Hematol 2010; 91: 30-35.
• 9 Diaz JA, Alvarado CM, Wrobleski SK. et al. The electrolytic inferior vena cava model (EIM) to study thrombogenesis and thrombus resolution with continuous blood flow in the mouse. Thromb Haemost 2013; 109: 1158-1169.
• 10 Banno F, Chauhan AK, Kokame K. et al. The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation. Blood 2009; 113: 5323-5329.
• 11 Akiyama M, Takeda S, Kokame K. et al. Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor. Proc Natl Acad Sci USA 2009; 106: 19274-19279.
• 12 Doi M, Matsui H, Takeda H. et al. ADAMTS13 safeguards the myocardium in a mouse model of acute myocardial infarction. Thromb Haemost 2012; 108: 1236-1238.
• 13 Kokame K, Nobe Y, Kokubo Y. et al. FRETSVWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
• 14 Becattini C, Agnelli G, Schenone A. et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366: 1959-1967.
• 15 Lotta LA, Tuana G, Yu J. et al. Next-generation sequencing study finds an excess of rare, coding single-nucleotide variants of ADAMTS13 in patients with deep vein thrombosis. J Thromb Hae-most 2013; 11: 1228-1239.
• 16 Zhao BQ, Chauhan AK, Canault M. et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 2009; 114: 3329-3334.
• 17 Fujioka M, Hayakawa K, Mishima K. et al. ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood 2010; 115: 1650-1653.
• 18 Khan MM, Motto DG, Lentz SR. et al. ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice. J Thromb Haemost 2012; 10: 1665-1671.
• 19 De Meyer SF, Savchenko AS, Haas MS. et al. Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice. Blood 2012; 120: 5217-5223.
• 20 Gandhi C, Khan MM, Lentz SR. et al. ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice. Blood 2012; 119: 2385-2391.